Adjuvant Endocrine Therapy in Hormone Receptor-Positive Postmenopausal Breast Cancer: Evolution of NCCN, ASCO, and St Gallen Recommendations

By Carlson Robert W.   Hudis Clifford A.   Pritchard Kathy I.  

Journal of the National Comprehensive Cancer Network (JNCCN), Vol. 4, Iss. 10, 2006-11 ,pp. : 971-979

Cambridge Scholars Publishing in association with GSE Research

Access to resources Recommend Favorite

Aromatase Inhibitors in Early Hormone Receptor-Positive Breast Cancer: What is the Optimal Initiation Time for the Maximum Benefit?

By Needleman Sarah J.   Tobias Jeffrey S.  

Drugs, Vol. 68, Iss. 1, 2008-01 ,pp. : 1-15

Adis International

Access to resources Recommend Favorite

Everolimus in the treatment of hormone receptor-positive breast cancer

By Chavez-MacGregor Mariana   Gonzalez-Angulo Ana Maria  

Expert Opinion on Investigational Drugs, Vol. 21, Iss. 12, 2012-12 ,pp. : 1835-1843

Informa Healthcare

Access to resources Recommend Favorite

Physical activity and survival of postmenopausal, hormone receptor–positive breast cancer patients: Results of the Tamoxifen Exemestane Adjuvant Multicenter Lifestyle study

By Glas Nienke A.   Fontein Duveken B. Y.   Bastiaannet Esther   Pijpe Anouk   De Craen Anton J. M.   Liefers Gerrit-Jan   Nortier Hans J. W. R.   Haes Hanneke J. C. J. M.   Velde Cornelis J. H.   Leeuwen Flora E.  

Cancer, Vol. 120, Iss. 18, 2014-09 ,pp. : 2847-2854

Blackwell Publishing

Access to resources Recommend Favorite

Switching to adjuvant exemestane after tamoxifen improves disease-free survival in postmenopausal women with hormone receptor-positive early breast cancer

By Adis International Limited  

Drugs & Therapy Perspectives, Vol. 23, Iss. 5, 2007-05 ,pp. : 1-4

Adis International

Access to resources Recommend Favorite